Friday, October 21, 2016

Guna-Beta-Estradiol




Generic Name: estradiol

Dosage Form: oral solution, drops
GUNA®-Beta-ESTRADIOL

1. INDICATIONS AND USAGE


1.1.    Regenerative Metabolic Support (use with GUNA-MATRIX, GUNA LYMPHO and GUNA-CELL)

1.2.    Female menstrual cycle disorders (use with GUNA-FEM)

1.3.    Infertility (use with GUNA-FEM)

1.4.    Aging and sagging skin

1.5.    Moderate hot flashes (use with GUNA-FEM)


Administration may vary according to individual needs.

GUNA®-BETA-ESTRADIOL may be used together with other homeopathic medications.




2. DOSAGE AND ADMINISTRATION


The usual initial dose of GUNA®-Beta-ESTRADIOL is:


Adults and children 14 years and older    20 drops in a little water, 2 times per day


for an average of two months. If response is not satisfactory, adjust treatment protocol as recommended by your health care professional.


3. DOSAGE FORMS AND STRENGTHS


3.1.    30 ml Bottle dropper.

3.2.    The ingredient is attenuated according to the procedures stated in the Homeopathic Pharmacopeia of the United States.

Beta-ESTRADIOL 6X.

Inactive Ingredient: Ethylic Alcohol 30%.




4. CONTRAINDICATIONS


4.1.    There is no history of hypersensitivity to GUNA®-Beta-ESTRADIOL. However Estradiol should not be taken by people with a hypersensitivity/allergy.

5. WARNINGS AND PRECAUTIONS


5.1.    Estradiol should not be  administered in cases where undiagnosed vaginal bleeding is present; in cases with known, actual or suspected history of breast cancer; during current treatment for metastatic disease;  with known or suspected estrogen-dependent neoplasia;  with deep vein thrombosis, pulmonary embolism or any history of these conditions; active or recent arterial thromboembolic disease such as stroke or myocardial infarction; or with liver dysfunction or disease.

5.2    Use with caution in patients taking estrogen and/or progesterone therapy.




6. ADVERSE REACTIONS


6.1. None known. (see CONTRAINDICATIONS for hypersensitivity information).



7. DRUG INTERACTIONS


7.1.    None Known.



8. USE IN SPECIFIC POPULATIONS


8.1.    Gender: Guna-Beta-Estradiol is indicated for use in women only.

8.2.    Pregnancy:  Estradiol should not be taken by people who are pregnant or suspected pregnancy. 

8.3.    Nursing mothers:    Since many drugs are secreted in human milk, caution should be exercised when GUNA®-Beta-ESTRADIOL is administered to a nursing woman.

8.4.    Pediatric use: Safety and effectiveness in pediatric patients have not been established. Estrogen treatment of prepubertal girls may induce premature breast development,  vaginal keratinization, and may induce vaginal bleeding. In boys, estrogen treatment may modify the normal pubertal process and induce gynecomastia.

8.5.    Geriatric use: No restrictions. (see USE IN SPECIFIC POPULATIONS, Gender).


9. DRUG ABUSE AND DEPENDENCE


9.1.    No Known.



10. OVERDOSAGE


10.1.    No Known.

11. DESCRIPTION


Guna-Beta-Estradiol is a biochemical homeopathic medication indicated for Regenerative Metabolic Support, Female menstrual cycle disorders, infertility, aging, sagging skin, and moderate hot flashes.

12. CLINICAL PHARMACOLOGY


12.1.    Mechanism of Action

The active ingredient in GUNA®-Beta-ESTRADIOL is a simple biochemical compound. The exact mechanism of action is unknown; however, due to the homeopathic nature of the active ingredient, receptors may be activated by feedback regulation. 

12.2.    Pharmacodynamics

In Homeopathy there is no direct relationship between dose and effect, but rather there is a relationship between attenuation and balancing effect on biochemical pathways.

The attenuation of the physiological ingredients promotes membrane receptor feedback in order to normalize altered biological pathways. In Addition, the attenuation technique activates the low dilutions and stabilizes clinical activity of the compound.

12.3.    Pharmacokinetics

Homeopathic attenuation provides complete bioavailability of the active ingredients.

13. NONCLINICAL TOXICOLOGY


13.1.    GUNA®-Beta-ESTRADIOL has no level of toxicity due to the attenuation of the ingredients.

14. CLINICAL STUDIES


14.1.    The GUNA®-Beta-ESTRADIOL formulation is based on Homeopathic principles.

15. HOW SUPPLIED/STORAGE AND HANDLING


15.1.    NDC  17089-359-18   Oral  Solution/Drops 30 mL

15.2.    Store at room temperature, 20-25°C (68-77° F). Avoid  freezing  and excessive  heat.

16. PATIENT COUNSELING INFORMATION


16.1.    Patients should be informed about Homeopathy and the main differences with conventional clinical approaches.



PACKAGE LABEL










Guna-Beta-Estradiol  
estradiol  solution/ drops










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)17089-359
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
ESTRADIOL (ESTRADIOL)ESTRADIOL6 [hp_X]  in 30 mL






Inactive Ingredients
Ingredient NameStrength
ALCOHOL9 mL  in 30 mL


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
117089-359-181 BOTTLE In 1 BOXcontains a BOTTLE, DROPPER
130 mL In 1 BOTTLE, DROPPERThis package is contained within the BOX (17089-359-18)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved homeopathic12/16/2008


Labeler - Guna spa (430538264)









Establishment
NameAddressID/FEIOperations
Guna spa430538264manufacture
Revised: 07/2010Guna spa




More Guna-Beta-Estradiol resources


  • Guna-Beta-Estradiol Use in Pregnancy & Breastfeeding
  • Drug Images
  • Guna-Beta-Estradiol Drug Interactions
  • Guna-Beta-Estradiol Support Group
  • 57 Reviews for Guna-Beta-Estradiol - Add your own review/rating


Compare Guna-Beta-Estradiol with other medications


  • Atrophic Urethritis
  • Atrophic Vaginitis
  • Breast Cancer, Palliative
  • Hypoestrogenism
  • Oophorectomy
  • Osteoporosis
  • Postmenopausal Symptoms
  • Primary Ovarian Failure
  • Prostate Cancer


No comments:

Post a Comment